Clinical Trial Update: Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cevimeline for radiation-induced dry mouth in head and neck cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• SALAGEN (Pilocarpine hydrochloride)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Head and Neck Cancer, Oral Complications | Phase 3 | Status: COMPLETED